102 related articles for article (PubMed ID: 3348944)
1. Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.
Osborne RJ; Malik ST; Slevin ML; Harvey VJ; Spona J; Salzer H; Williams CJ
Br J Cancer; 1988 Jan; 57(1):115-6. PubMed ID: 3348944
[No Abstract] [Full Text] [Related]
2. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.
de Vos D; Slee PH; Briggs RJ; Stevenson D
Cancer Chemother Pharmacol; 1998; 42(6):512-4. PubMed ID: 9788580
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
Wagner U; du Bois A; Pfisterer J; Huober J; Loibl S; Lück HJ; Sehouli J; Gropp M; Stähle A; Schmalfeldt B; Meier W; Jackisch C;
Gynecol Oncol; 2007 Apr; 105(1):132-7. PubMed ID: 17161453
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of tamoxifen in ovarian cancer.
Slevin ML; Harvey VJ; Osborne RJ; Shepherd JH; Williams CJ; Mead GM
Eur J Cancer Clin Oncol; 1986 Mar; 22(3):309-12. PubMed ID: 3709599
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen therapy for advanced ovarian cancer.
Schwartz PE; Keating G; MacLusky N; Naftolin F; Eisenfeld A
Obstet Gynecol; 1982 May; 59(5):583-8. PubMed ID: 7070729
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.
Markman M; Iseminger KA; Hatch KD; Creasman WT; Barnes W; Dubeshter B
Gynecol Oncol; 1996 Jul; 62(1):4-6. PubMed ID: 8690289
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules.
Fabian C; Sternson L; Barnett M
Cancer Treat Rep; 1980; 64(6-7):765-73. PubMed ID: 7427961
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of efficacy and toxicity of tamoxifen in patients with advanced chemotherapy resistant ovarian cancer].
Rolski J; Pawlicki M
Ginekol Pol; 1998 Jul; 69(7):586-9. PubMed ID: 9810419
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of tamoxifen for advanced and recurrent breast cancer (author's transl)].
Horumon To Rinsho; 1980 Apr; 28(4):425-36. PubMed ID: 7006865
[No Abstract] [Full Text] [Related]
10. Tamoxifen therapy of epithelial ovarian cancer.
Shirey DR; Kavanagh JJ; Gershenson DM; Freedman RS; Copeland LJ; Jones LA
Obstet Gynecol; 1985 Oct; 66(4):575-8. PubMed ID: 4047546
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer and duration of tamoxifen.
Prescrire Int; 2015 Sep; 24(163):220. PubMed ID: 26417636
[TBL] [Abstract][Full Text] [Related]
12. Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma.
Riippa P; Kauppila A; Sundström H; Vihko R
Anticancer Res; 1984; 4(3):109-12. PubMed ID: 6235770
[TBL] [Abstract][Full Text] [Related]
13. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
George A; McLachlan J; Tunariu N; Della Pepa C; Migali C; Gore M; Kaye S; Banerjee S
BMC Cancer; 2017 Jun; 17(1):456. PubMed ID: 28666422
[TBL] [Abstract][Full Text] [Related]
14. [A case of recurrent breast cancer responding to long-term administration of tamoxifen].
Yayoi E; Kobayashi T; Inaji H; Maeura Y; Mori T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1683-6. PubMed ID: 6433801
[TBL] [Abstract][Full Text] [Related]
15. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer.
Markman M; Webster K; Zanotti K; Rohl J; Belinson J
Gynecol Oncol; 2004 May; 93(2):390-3. PubMed ID: 15099951
[TBL] [Abstract][Full Text] [Related]
16. Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.
Stewart JF; Minton MJ; Rubens RD
Cancer Treat Rep; 1982 Jun; 66(6):1445-6. PubMed ID: 7044536
[No Abstract] [Full Text] [Related]
17. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
[TBL] [Abstract][Full Text] [Related]
18. High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator.
Millward MJ; Lien EA; Robinson A; Cantwell BM
Oncology; 1994; 51(1):79-83. PubMed ID: 8265108
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant endocrine therapy for premenopausal women: Type and duration.
Francis PA
Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer.
Hofstra LS; Mourits MJ; de Vries EG; Mulder NH; Willemse PH
Anticancer Res; 1999; 19(4C):3627-30. PubMed ID: 10629663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
